Eli Lilly’s Obesity Pill Hits Key Targets, Boosts Weight Loss in Type 2 Diabetes Trial
A needle-free alternative is on the way. Eli Lilly’s daily obesity pill, orforglipron, met key goals in a major...
A needle-free alternative is on the way. Eli Lilly’s daily obesity pill, orforglipron, met key goals in a major...
Morgan Stanley analysts are setting a bullish tone for the upcoming earnings season, with specific companies expected to outperform....
U.S. stock futures were mixed Monday, with strength in the Dow and S&P 500, while weakness in AI bellwether Nvidia...